Foxes in the henhouse: Another biopharma exec busted for insider trading
This article was originally published in Scrip
Executive Summary
Investors were not the only ones hungry for Array Biopharma's shares in the spring of 2010 in reaction to a mega deal with Swiss drug and vaccine maker Novartis, which paid out $45 million up front to the Boulder, Colorado-based biotech, adding an additional $422 million on the achievement of certain milestones.